Chairman of the Board
He was a researcher in the cancer institute in Villejuif and then in the cancer and immunogenetics institute (INSERM-CNRS) founded by professor Georges Mathe. In 1986, he founded MS Medical Synergy, a company that specializes in drug management, after which he joined Biovector Therapeutics and became chairman and CEO.
Emile Loria is chairman and co-founder of OSE Pharma. He has more than 25 years of experience in the pharmaceutical and biotechnology sectors, occupying key positions, in particular with Ciba-Geigy and Sanofi Pharma.
Gérard Tobelem is a former haematology professor at Paris 7 University and former Head of the department of blood disorders at the Lariboisière hospital in Paris, as well as past Executive Chairman of the French Blood Establishment. Gérard Tobelem’s research work was recognized when, in 2006, he was awarded the first Diderot Innovation prize. He has practised strategic functions within the French Ministry of Higher Education and Research and has also advised different international pharmaceutical companies in their R&D strategies. Mr. Tobelem currently serves as non-executive Chairman of the Board of Directors of Theradiag.
Graduated Doctor of Medicine from the University of Liège in 1987, Philippe Lefebvre had already acquired experience in the field of research during his studies since 1981 under the direction of Professor Gustave Moonen. He earned the title of Doctor of Biomedical Science in 1991 after writing a paper on the neurobiology of the inner ear. In 1991, he obtained recognition in Otolaryngology. He completed a postdoctoral fellowship at the Albert Einstein College of Medicine in New York where he continued his work on the neurobiology of the inner ear and acquired advanced ear surgery skills. In 1997, he was appointed clinical professor at the University of Liège. In 2002, he was appointed Professor of ENT at the University of Liège and Head of the ENT Department, a post he still holds today. Philippe Lefebvre has gained a worldwide reputation in the field of the neurobiology of the inner ear, in the pathophysiology of deafness and in the treatment of hearing loss. He is invited to present conferences and to operate in many countries. He has over 130 publications in international journals and sits on many national and international boards. He is a member of the Royal Academy of Medicine of Belgium. He has received numerous scientific awards for his research on deafness, among which we can quote the Prix Gallien.
With more than 25 years of experience in management positions in the pharmaceutical industry,
Stéphane already has to his credit as an inventor and entrepreneur a "success story" relating to the development of a breakthrough technology, "an innovative formulation of ice cream packaged in an innovative aerosol container", generating several patents ceded after eight years at multinational Nestlé.
In 2002, Stéphane Silvente founded and led as CEO Affichem, a biotech company in oncology neurology and dermatocosmetic.
In 2018, Stpéhane was CEO of Dendrogenix, a biotech company in neurodegenrative and cancer therapy.
Stéphane Silvente graduated from the EDC Paris Business School (Ecole des Cadres renamed Ecole des Créateurs d'Entreprises), a DESS "Trilingual Negotiator of International Trade" from the Faculty of Valenciennes, a Master's degree (MBA in Innovation Marketing and Food Transfer) Toulouse Sup de Co (TBS / Toulouse Business School).